A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
NCT06299111
Recruiting
This study is researching 2 different experimental drugs called REGN9933 and REGN7508 (called "study drugs"). The study is focused on adults undergoing a placement of a catheter in the vein, also called a 'PICC line'. The aim of the study is to see how effective the study drug is at preventing venous thromboembolism (VTE) and other related disease after catheter placement. The study is looking at several other research questions, including: * What side effects may happen from taking the study... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Sylvester Comprehensive Cancer Center, Miami, Florida +18 locations
Conditions: Venous Thromboembolism
Register for Updates
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
NCT06311721
Recruiting
The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/13/2025
Locations: Precision NextGen Oncology and Research Center, Beverly Hills, California +194 locations
Conditions: Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Register for Updates
DECIDE to Improve Maternal Mental Health Care Delivery
NCT07098260
Recruiting
Appropriate training for perinatal mental health care is an important public health concern as mental health disorders are common pregnancy complications. Perinatal and mental health care providers report the difficulty of treating perinatal individuals due to insufficient information available regarding mental health treatment decisions, differences in beliefs and attitudes, and concerns about adverse effects on patients, such as self-harm and suicide. Effective shared decision-making skills ca... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
08/13/2025
Locations: Rutgers, the State University of New Jersey, Piscataway, New Jersey
Conditions: Mental Health Disorders
Register for Updates
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
NCT06668493
Recruiting
The primary purpose of this trial is to evaluate the safety \& tolerability of Nadofaragene Firadenovec in subjects with LG-UTUC. To help with this evaluation, a safety lead-in period will be conducted for the first 6 subjects. Complete response is at 3 or 6 months defined as absence of any UTUC in the renal pelvis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Indiana University, Indianapolis, Indiana +2 locations
Conditions: Low-grade Upper Tract Urothelial Carcinoma
Register for Updates
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
NCT07094204
Recruiting
Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. ASP5834 is being studied in people with solid tumors who have certain KRAS gene mutations. Some people with solid tumors of the colon or rectum (colorectal cancer), will be given ASP5834 with panitumumab. Panitumumab is a treatment for colo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: START Midwest, Grand Rapids, Michigan +2 locations
Conditions: Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Register for Updates
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073
Recruiting
Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the bladder. High-risk means NMIBC may have a high chance of getting worse or coming back after treatment. HR NMIBC can also include carcinoma in situ (CIS). CIS is bladder cancer that appears flat and is only in the inner layer (surface) of the bladder. CIS is n... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Michael G Oefelein Clinical Trials ( Site 0138), Bakersfield, California +53 locations
Conditions: Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
Register for Updates
Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators
NCT07133880
Recruiting
The purpose of this study is to compare the effectiveness of inhaled bronchodilators delivered via nebulizers vs. dry powder inhalers (DPIs) in symptomatic participants with Chronic Obstructive Pulmonary Disease (COPD) who have airflow obstruction (FEV1/FVC ≤ 70%) and show significant air trapping (RV ≥ 120% of predicted). We hypothesize that, in patients with symptomatic COPD, therapy with a long-acting anti muscarinic agent/long-acting beta agonist (LAMA/LABA) combination administered by nebu... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/13/2025
Locations: The University of Tennessee Graduate School of Medicine, Knoxville, Tennessee
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Register for Updates
Breathwork Intervention for Posttraumatic Stress
NCT07129278
Recruiting
The goal of this single-site, single-arm pilot study is to examine the impact of breathwork training for posttraumatic stress symptoms in an adult veteran population. Participants will complete a single, in-person breathwork session (2 hours) led by a certified breathwork facilitator and engage in an integration session (30 minute) with a licensed psychologist. Participants will be invited to engage in two, optional, virtual follow up breathwork sessions (40 minute practice each) during weeks 2... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Diamond Rose Sanctuary, Branford, Connecticut +1 locations
Conditions: PTSD
Register for Updates
Aromatherapy Essential Oils to Manage Anxiety and Nausea in Cancer Patients Receiving Infusion in the Ambulatory Setting
NCT07126301
Recruiting
This clinical trial tests how well aromatherapy essential oils work to manage anxiety and nausea in cancer patients receiving infusions in the ambulatory setting. Current drugs that are given for nausea may cause constipation and fatigue. Therefore, there is interest in exploring complementary therapies, like aromatherapy, that do not carry the same side effects. Using aromatherapy essential oils such as ginger, peppermint, and lavender, may help reduce nausea and anxiety. Some studies have show... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: City of Hope Medical Center, Duarte, California +1 locations
Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Register for Updates
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
NCT07133308
Recruiting
This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
08/13/2025
Locations: Total Skin And Beauty Dermatology Center, Birmingham, Alabama +21 locations
Conditions: Alopecia Areata
Register for Updates
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
NCT06088199
Recruiting
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
08/13/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +29 locations
Conditions: Plaque Psoriasis
Register for Updates
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
NCT06083844
Recruiting
To find out if combining pembrolizumab, bevacizumab (or an equivalent biosimilar drug), and low-dose cyclophosphamide can help control high-grade ovarian cancer that has MRD after treatment. The safety of this treatment combination will also be studied.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York +1 locations
Conditions: Ovarian Cancer
Register for Updates